HeartBeam, Inc. (BEAT) stock
Close on Oct 30, 2026Market cap $659.29KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $659.29K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.08
- Dividend yield
- –
- Free cash flow yield
- -2125.18%
Fundamentals
- Net income
- -$20.30M
- EPS, diluted
- -$0.52
- Free cash flow
- -$14.01M
- Book value per share
- $0.15
- Diluted shares
- 53M
Trading
- Previous close
- $0.54
- Open
- $0.54
- Day's range
- $0.52 – $0.56
- Volume
- 1,696,176
- Average volume (20 days)
- 22,679,693
- Beta (5 years)
- -0.08
- 52-week range
- $0.00 – $0.56
- RSI (14 days)
- 48.8
- Volatility (1 year)
- 616.8%
- Relative volume
- 3.43×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | BEAT | S&P 500 | Difference | BEAT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +50.0% | -0.9% | +50.9 pts | ||
| 3 months | +6.3% | +2.1% | +4.2 pts | ||
| Year to date | -77.1% | +11.7% | −88.8 pts | ||
| 1 year | -65.8% | +12.4% | −78.2 pts | ||
| 3 years | -51.3% | +88.6% | −139.9 pts | -21.3% | +23.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases HeartBeam filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Update
- News
About HeartBeam
Surgical & Medical Instruments & Apparatus
HeartBeam is a medical technology company that develops ambulatory cardiac monitoring solutions designed for use outside clinical environments. The company's primary offering is the HeartBeam System, a cable-free cardiac monitoring platform comprising a credit-card-sized three-dimensional electrocardiogram (ECG) recording device, a patient mobile application, cloud-based algorithms, and a web-based physician portal. The system records electrical signals from the heart across three dimensions to synthesize twelve-lead ECG readings for remote arrhythmia assessment, supported by continuous access to on-demand cardiologists. Target customers include concierge physicians, preventive cardiology practices, and hospital cardiology departments.
Company profile, executives and historyHeartBeam stock: common questions
What is HeartBeam's stock price?
BEAT closed at $0.55 on Oct 30, 2026, up 2.06% on the day. Over the past 52 weeks it traded between $0.00 and $0.56.
What is HeartBeam's market cap?
HeartBeam was worth $659.29K at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is BEAT's P/E ratio?
HeartBeam lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.52), so it has no meaningful P/E ratio.
Does HeartBeam pay a dividend?
No. HeartBeam has not paid a cash dividend over the last twelve months.
How has BEAT stock performed over the past year?
Including dividends, BEAT returned -65.8% over the past year, against +12.4% for the S&P 500.
Who are HeartBeam's competitors?
Companies most similar to HeartBeam by business, industry and size include BTCY, IRTC, EBRCZ, CVRX, KMTS.